These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 22427054)

  • 21. Adipocyte-conditioned medium induces tamoxifen resistance by activating PI3K/Akt/mTOR pathway in estrogen receptor-positive breast cancer cells.
    Nakatsuji M; Fujimori K
    Biochim Biophys Acta Mol Cell Res; 2024 Oct; 1871(7):119821. PubMed ID: 39159684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.
    Heckler MM; Thakor H; Schafer CC; Riggins RB
    FEBS J; 2014 May; 281(10):2431-42. PubMed ID: 24684682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis.
    Yin H; Zhu Q; Liu M; Tu G; Li Q; Yuan J; Wen S; Yang G
    Int J Oncol; 2017 Oct; 51(4):1191-1198. PubMed ID: 28902352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin.
    Mabuchi S; Ohmichi M; Kimura A; Ikebuchi Y; Hisamoto K; Arimoto-Ishida E; Nishio Y; Takahashi K; Tasaka K; Murata Y
    Endocrinology; 2004 Mar; 145(3):1302-13. PubMed ID: 14645110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in MCF-7 human breast cancer cells.
    Park SK; Hwang YS; Park KK; Park HJ; Seo JY; Chung WY
    Carcinogenesis; 2009 Jul; 30(7):1225-33. PubMed ID: 19420016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
    Thomas NB; Hutcheson IR; Campbell L; Gee J; Taylor KM; Nicholson RI; Gumbleton M
    Breast Cancer Res Treat; 2010 Feb; 119(3):575-91. PubMed ID: 19288272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P; Wang J; Santen RJ; Yue W
    Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
    Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
    Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
    Shi YF; Lu H; Wang HB
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of proliferation of estrogen receptor‑positive MCF‑7 human breast cancer cells by tamoxifen through c‑Jun transcription factors.
    Xu Y; Zou ST; Zhu R; Li W; Gu CW; Wei SH; Xie JM; Wu HR
    Mol Med Rep; 2013 Apr; 7(4):1283-7. PubMed ID: 23404426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.
    De Vincenzo R; Scambia G; Benedetti Panici P; Fattorossi A; Bonanno G; Ferlini C; Isola G; Pernisco S; Mancuso S
    Int J Cancer; 1996 Nov; 68(3):340-8. PubMed ID: 8903476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
    Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
    Chen J; Power KA; Mann J; Cheng A; Thompson LU
    Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen.
    Chen JL; Chang CJ; Wang JY; Wen CS; Tseng LM; Chang WC; Noomhorm N; Liu HJ; Chen WS; Chiu JH; Shyr YM
    Integr Cancer Ther; 2014 May; 13(3):226-39. PubMed ID: 24525674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
    Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
    Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells.
    Zhang L; Ren X; Cheng Y; Huber-Keener K; Liu X; Zhang Y; Yuan YS; Yang JW; Liu CG; Yang JM
    Biochem Pharmacol; 2013 Sep; 86(6):726-33. PubMed ID: 23856293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase.
    Ismail A; Doghish AS; E M Elsadek B; Salama SA; Mariee AD
    Steroids; 2020 Aug; 160():108656. PubMed ID: 32439410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
    Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
    Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.